Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131245 | 0.92 | ALDH1A1 (0.34) | LIPGNAMPTSLC40A1LIPC | |
| SCHEMBL4127584 | 0.92 | HTR6 (0.35) | LIPGNAMPTDHODHGRM4LIPC | |
| SCHEMBL4125431 | 0.90 | DHODH (0.36) | NAMPTDHODHGRM4SLC40A1 | |
| SCHEMBL4125989 | 0.88 | GAA (0.36) | NAMPTCYP2C9PIP4K2APIP4K2C | |
| SCHEMBL4118456 | 0.88 | LIPG (0.33) | LIPGDHODHGRM4SLC40A1LIPC | |
| SCHEMBL4137731 | 0.88 | NFE2L2 (0.38) | NAMPTSLC40A1 | |
| SCHEMBL4118513 | 0.88 | MAPT (0.37) | HTTPTGS2 | |
| SCHEMBL4130442 | 0.86 | KMT2A (0.38) | NAMPT | |
| SCHEMBL4132297 | 0.83 | KMT2A (0.39) | NAMPTCYP2C9ATM | |
| SCHEMBL4118036 | 0.81 | DHODH (0.36) | LIPGDHODHSLC40A1LIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | LIPG 2467/4885NAMPT 2129/4885CYP2C9 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.